Compare · ARPO vs AZRX
ARPO vs AZRX
Side-by-side comparison of Aerpio Pharmaceuticals, Inc. (ARPO) and AzurRx BioPharma, Inc. (AZRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARPO and AZRX operate in Major Pharmaceuticals (Health Care), so they compete in similar markets.
- ARPO is the larger of the two at $425.1M, about 12.4x AZRX ($34.4M).
- Both have 1 recent analyst rating on file.
- Company
- Aerpio Pharmaceuticals, Inc.
- AzurRx BioPharma, Inc.
- Price
- $2.19-1.57%
- $3.46+2.67%
- Market cap
- $425.1M
- $34.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Major Pharmaceuticals
- Major Pharmaceuticals
- Exchange
- NASDAQ
- NASDAQ
- IPO
- n/a
- 2016
- News (4w)
- 0
- 0
- Recent ratings
- 1
- 1
Aerpio Pharmaceuticals, Inc.
Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing compounds that activate Tie2 for the treatment of ocular disease and vascular stabilization. The company's lead product candidate is razuprotafib, a small molecule inhibitor of vascular endothelial protein tyrosine phosphatase , which has completed phase IIb clinical trial for the treatment of non-proliferative diabetic retinopathy, as well as has completed phase II clinical trial for the treatment of patients with open angle glaucoma/ocular hypertension. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications, including nephropathy and diabetic macular edema; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals, Inc. has a licensing and collaboration agreement with Gossamer Bio, Inc. for the development and commercialization of GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed Phase 1b clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio.
AzurRx BioPharma, Inc.
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is based in Boca Raton, Florida.
Latest ARPO
- SEC Form EFFECT filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-8 filed by Aerpio Pharmaceuticals, Inc.
- SEC Form S-3 filed by Aerpio Pharmaceuticals, Inc.
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Financial Statements and Exhibits (Amendment)
- SEC Form 4 filed by Delaney Brendan
- SEC Form 3 filed by new insider Delaney Brendan
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Aerpio Pharmaceuticals, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Desai Neil
- SEC Form 4 filed by Reeve Emma
Latest AZRX
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Other Events
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
- SEC Form 4 filed by Coelho Mary Theresa
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
- AzurRx BioPharma, Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- AzurRx BioPharma Announces Reverse Stock Split